LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on spinocerebellar ataxia. The report includes a detailed analysis of the pipeline molecules under ...

According to DelveInsight's analysis, the market size for Friedreich's ataxia is anticipated to surge at a significant rate by 2034. The prevalence of Friedreich's ataxia in the United States has been ...

Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...

DelveInsight's“ Friedreich's Ataxia Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Friedreich's Ataxia pipeline landscape. It covers ...

The US FDA has approved Reata Pharmaceuticals' (NASDAQ:RETA) Friedreich's ataxia (FA) treatment omaveloxolone. Branded as Skyclarys, the drug is approved for those 16 years and older with the ...

LAS VEGAS, June 5, 2025 /PRNewswire/ -- DelveInsight's Friedreich's Ataxia Market Insights report includes a comprehensive understanding of current treatment practices, Friedreich's ataxia emerging ...

SAN DIEGO--(BUSINESS WIRE)--Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this disease.

Horizon Pharma PLC said Friday that its experimental Friedreich’s ataxia treatment has received fast-track designation from the U.S. Food and Drug Administration, a move that could speed approval. The ...